Literature DB >> 17327745

Acute liver failure: liver support therapies.

Vanessa Stadlbauer1, Rajiv Jalan.   

Abstract

PURPOSE OF REVIEW: We summarize the therapeutic approach to patients with acute liver failure with the main focus on bioartificial and artificial liver support. We also describe specific and general therapeutic approaches based upon recent advances in the understanding of the pathophysiology of acute liver failure. RECENT
FINDINGS: Bioartificial liver support systems use hepatocytes in an extracorporeal device connected to the patient's circulation. Artificial liver support is intended to remove protein-bound toxins and water-soluble toxins without providing synthetic function. Both systems improve clinical and biochemical parameters and can be applied safely to patients. Although bioartificial liver-assist devices have not been shown to improve the survival of patients with acute liver failure, further development is underway. Artificial liver support systems have been shown to alter several pathophysiological mechanisms involved in the development of acute liver failure but survival data are still limited.
SUMMARY: Mortality in patients with acute liver failure is still unacceptably high. The most effective treatment, liver transplantation, is a limited resource and so other therapeutic options to bridge patients to recovery or stabilization have to be considered. Better understanding of the pathophysiology of acute liver failure and device development is necessary to achieve the elusive goal of effective extracorporeal liver assist.

Entities:  

Mesh:

Year:  2007        PMID: 17327745     DOI: 10.1097/MCC.0b013e328052c4cc

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  9 in total

1.  Future of bioartificial liver support.

Authors:  Robert Afm Chamuleau
Journal:  World J Gastrointest Surg       Date:  2009-11-30

2.  Endotoxin tolerance alleviates experimental acute liver failure via inhibition of high mobility group box 1.

Authors:  Nai-Bin Yang; Shun-Lan Ni; Shan-Shan Li; Sai-Nan Zhang; Dan-Ping Hu; Ming-Qin Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 3.  Neurological management of fulminant hepatic failure.

Authors:  Jennifer A Frontera; Thomas Kalb
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

Review 4.  An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.

Authors:  María-Jesús Tuñón; Marcelino Alvarez; Jesús-M Culebras; Javier González-Gallego
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

5.  Enhanced expressions and activations of leukotriene C4 synthesis enzymes in D-galactosamine/lipopolysaccharide-induced rat fulminant hepatic failure model.

Authors:  Kui-Fen Ma; Hong-Yu Yang; Zhe Chen; Luo-Yang Qi; Dan-Yan Zhu; Yi-Jia Lou
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

6.  Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.

Authors:  Gadi Lalazar; Tomer Adar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

7.  Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure.

Authors:  Shibin Jacob; Ahmed Khan; Elizabeth R Jacobs; Prem Kandiah; Rahul Nanchal
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

8.  Modifying three-dimensional scaffolds from novel nanocomposite materials using dissolvable porogen particles for use in liver tissue engineering.

Authors:  Hussamuddin Adwan; Barry Fuller; Clare Seldon; Brian Davidson; Alexander Seifalian
Journal:  J Biomater Appl       Date:  2012-04-24       Impact factor: 2.646

Review 9.  Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory.

Authors:  Henning C Fiegel; Peter M Kaufmann; Helge Bruns; Dietrich Kluth; Raymund E Horch; Joseph P Vacanti; Ulrich Kneser
Journal:  J Cell Mol Med       Date:  2007-11-16       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.